WHEAT RIDGE, CO -- (MARKET WIRE) -- 05/07/07 -- GeneThera, Inc. (OTCBB: GTHA) announced today it is expanding its marketing program for its Mad Cow testing kit to include foreign markets. The marketing campaign is being designed to build brand awareness with the ranchers and slaughterhouses around the world.

Japan and some European countries test 100% of the cattle that are slaughtered. All of the current tests in these countries are done after the cattle have been slaughtered. GeneThera's test, however, is tested on live cattle which would save slaughterhouses considerable time and money by identifying the sick cattle prior to slaughter. Additionally, it will allow ranchers to segregate cattle that are infected from healthy cattle. The ability to test on live cattle will provide GeneThera a clear advantage against other testing methods.

Dr. Tony Milici, CEO of GeneThera, stated, "We will continue to work on our live animal testing program of Mad Cow Disease in foreign countries particularly in Europe where GeneThera has a greater market opportunity due to the large number of tests being done."

There are approximately 1.3 Billion cattle worldwide.

ABOUT GENETHERA, INC.:

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression system, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priority being Mad Cow Disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.